CUE · Cue Biopharma, Inc. · Metrics
$25.87
+0.36 (+1.41%)
At close · Sep 30
Return incl. dividend (before tax)
Going-concern doubt
— cleared Aug 14, 2026
The latest filing no longer states the doubt (first flagged May 14, 2026).
View the 10-Q filed Aug 14, 2026Market Cap
$194.11M
Shares
7.26M
Volume · Sep 30
228.12K
Avg daily vol (3M)
260.76K
CUE metrics
59 of 115 screener metrics currently available.
Market overview
2 metricsShare price
$25.87
Market cap
$194.11M
Price action
20 metricsPrice change (1W)
-17.4%
Price change (30D)
0.0%
Price change (3M)
-19.2%
Price change (6M)
—
Price change (YTD)
—
Price change (1Y)
—
Trailing year
Price change (5Y)
—
52-week high
—
52-week low
—
Change from 52-week high
—
Change from 52-week low
—
Annualized volatility
211.2%
Annualized volatility (3M)
124.3%
Beta
2.6
RSI (14D)
42.2
Price vs SMA 50
-12.7%
Price vs SMA 200
—
Avg volume (3M)
260,952
Relative volume
1.1
Average dollar volume
$7.75M
Company
3 metricsSector
Healthcare
Industry
Biotechnology
Shares outstanding
7.26M
Valuation
12 metricsP / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
6.0×
reciprocal yield 16.8%
P / book
97.2
reciprocal yield 1.0%
FCF yield
-22.3%
TTM · current market cap
Buyback yield
0.0%
P / FCF
—
P / operating cash flow
—
Earnings yield
-73.1%
Historical valuation
8 metricsP / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
49.2×
reciprocal yield 2.0%
EV / revenue historical average (5Y)
43.0×
reciprocal yield 2.3%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—
Dividends & buybacks
7 metricsDividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
0.0%
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—
Earnings calendar
2 metricsNext earnings
—
Last earnings
2026-09-21
Profitability
9 metricsGross margin
—
Operating margin
-262.0%
Trailing 12 months
Net margin
-435.8%
Gross profit (TTM)
—
Operating profit (TTM)
−$98.67M
Net income (TTM)
−$164.11M
Trailing 12 months
Diluted EPS (TTM)
$-26.00
FCF margin
-133.2%
Effective tax rate
—
Growth
11 metricsRevenue growth YoY
+166.7%
Year over year
Net income growth YoY
—
Revenue (TTM)
$37.65M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+99.3%
Year over year · more shares
Revenue CAGR (3Y)
+180.5%
Revenue CAGR (5Y)
+54.2%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—
Quality
14 metricsReturn on equity
-7,104.2%
Return on assets
-534.4%
Debt / equity
—
Current ratio
1.3
EBITDA (TTM)
−$97.31M
Free cash flow (TTM)
−$50.17M
Quick ratio
1.3
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$17.39M
Total assets
$30.71M
Total debt
—
Cash flow & spend
7 metricsOperating cash flow (TTM)
−$50.05M
Capital expenditures (TTM)
$121,000
R&D (TTM)
$77.19M
SG&A (TTM)
—
Stock compensation (TTM)
$26.03M
R&D / revenue
205.0%
Stock compensation / revenue
69.1%
Ownership (13F)
3 metrics13F filers
51
13F filer change QoQ
-7
Institutional ownership
23.4%
Short interest
3 metricsShort interest
4.6%
Latest settlement · 2.4 days to cover
Days to cover
2.4d
Short-squeeze score
55 / 100
Insider activity
2 metricsNet insider buying (90D)
−$2.04M
Insider-sentiment score
14 / 100
Risk flags
1 metricsGoing concern
—